This suggested that potentially ‘oncogenic’ effectors of SRF/IGF2BP1 are identified by a conserved positive association with SRF/IGF2BP1-expression in cancer and downregulation upon SRF and IGF2BP1 depletion in cancer-derived cells. The gene discussed is SRF; the disease is cancer.